Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches).

This trial compares the effect of two different types of coaching for people living with Rheumatoid Arthritis (RA). Living with RA is difficult, and some people will also experience challenges with stress, anxiety, and difficult emotions (depressive or sad symptoms).

This research study is being done to learn more about the study drug 68Ga-PSMA-11. The study drug is composed of a radioactive substance called gallium-68 (68Ga) combined with a substance that attaches to a protein called PSMA (Prostate-Specific Membrane Antigen), which is found in large amounts on prostate cancer cells. 68Ga-PSMA-11 combined with CT or MRI may help regular doctors see where possible prostate cancer lesions are, even in places that regular scans like MRI might miss.

The main purpose of this study is to investigate whether the study drug, trontinemab, is able to slow down the worsening of symptoms in participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia. 

Trontinemab combines an anti-amyloid antibody with a module that helps deliver the antibody more efficiently to the brain. Once in the brain, trontinemab works by removing amyloid-beta plaques, a protein associated with Alzheimer’s disease.

The purpose of this prescreening study is to identify people that may be eligible for future clinical trials that test new drugs for Alzheimer’s disease.

We hope to learn about the efficacy of using Bone Marrow Aspirate Concentrate (BMAC) during temporomandibular joint (TMJ) arthroscopy compared to standard arthroscopic procedures with corticosteroid (CS) injections. We are recruiting patients that have a diagnosis of pain (arthralgia) of the temporomandibular joint (TMJ) that has failed to respond to conservative treatment.
   
Participants will be randomized to receive either BMAC or CS injection during TMJ arthroscopy. There is an equal chance of you being in either intervention group.

The overall goal of this study is to understand patients’ perceptions of dashboard-based screening and intervention matching. Dashboard-based screening and intervention matching means that we are using the collection of patients’ responses to surveys to match patients to studies that may be fitting or beneficial to them. These studies are then introduced to the patient, and they can choose to participate. 
   

In this study, we are trying to improve treatment of Favorable Histology Wilms Tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype.

This study involves new treatments and some usual treatments for FHWT. We will use results of biology tests to make treatment decisions. We may also use the tumor’s early response to treatment to guide further therapy.

This clinical research study aims to investigate the safety and efficacy of a study drug called vonoprazan, a potassium-competitive acid blocker, for treating Eosinophilic Esophagitis (EoE). EoE is characterized by an excessive presence of eosinophils in the esophagus, leading to inflammation and symptoms such as difficulty swallowing, chest pain, and nausea. The main objective of the study is to assess the effectiveness of vonoprazan in alleviating the symptoms of EoE and improving patient outcomes.

The purpose of this study is to evaluate the safety and effectiveness of AAA817 and an Androgen receptor pathway inhibitor (ARPI) given compared to the standard of care options.
   
AAA817 is experimental, which means it is being tested and is not yet approved by the United States Food and Drug Administration (FDA).
   
In this study, AAA817 will be given intravenously (meaning through a needle in the vein directly into the blood). The Androgen receptor pathway inhibitor (ARPI) will be given orallly.